Alliance A222001
Trial Overview
Official Title
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin versus Placebo for Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy
Study Purpose
To test whether a low or high dose of oxybutynin can reduce hot flashes.
Diagnosis
Hormone therapy treatments for your prostate cancer can cause side effects such as hot flashes.Eligibility
Prostate Cancer
Men receiving androgen deprivation therapy (hormone therapy)
Intervention
Group 1: Patients will take oxybutynin 2.5 ml two times a day for up to six weeks.
Group 2: Patients will take placebo 2.5 ml two times a day for up to six weeks.
Group 3: Patients will take oxybutynin 5.0 ml two times a day for up to six weeks.
Group 4: Patients will take placebo 5.0 ml two times a day for up to six weeks.
Patients will also complete questionnaires before you start study treatment, daily during treatment, and at the end of treatment.
For more information, visit Clinicaltrials.gov